Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
1. FDA approved Vertex's Alyftrek for cystic fibrosis in adults and kids. 2. Vertex estimates CF patients at 94,000; reimbursement may help 10,000 more. 3. Suzetrigine aims for FDA approval, could transform pain management landscape. 4. Analyst predicts many patients will switch to Alyftrek for cystic fibrosis. 5. Suzetrigine may have higher pricing, impacting initial market performance.